UK: NICE published draft guidance in which enzalutamide is not recommended as a drug to treat advanced prostate cancer.  It says enzalutamide. also called Xtandi, manufactured by Astellas Pharma) is not a cost effective, pre chemotherapy treatment with too many uncertainties associated with evidence provided by manufacturer.  …more

Leave a Comment

I accept the Privacy Policy

This site uses Akismet to reduce spam. Learn how your comment data is processed.